



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

|               |  |
|---------------|--|
| Last Trade:   | 2.23   |
| Trade Time:   | 8:00 PM ET<br>05/25/18                             |
| Change:       | 0.07 <span style="color: green;">↑</span> (3.241%) |
| Day Range     | 2.15 - 2.25  |
| 52-Week Range | 1.42 - 4.37  |
| Volume        | 282,664  |


Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [05/15/18  
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)
- [05/07/18  
Rexahn Reports First Quarter 2018 Financial Results](#)
- [04/26/18  
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)
- [03/13/18  
Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)
- [03/12/18  
Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- [03/09/18  
Annual Report \(10-K\)](#)
- [04/23/18  
Proxy Statement \(DEF 14A\)](#)
- [05/04/18  
Quarterly Report \(10-Q\)](#)
- [11/03/17  
Quarterly Report \(10-Q\)](#)
- [08/04/17  
Quarterly Report \(10-Q\)](#)